SK C&C Takes First Step into North American Healthcare Market with Brain Hemorrhage Diagnosis Support Software

[Asia Economy Reporter Kang Nahum] SK Inc. C&C is taking its first step into the North American healthcare market.

SK C&C announced on the 25th that it will showcase its AI-based brain hemorrhage diagnostic support software, "Medical Insight+ Brain Hemorrhage," at the "Radiological Society of North America (RSNA) 2021" held in Chicago, USA, on the 28th.

The Radiological Society of North America is the world's largest radiology academic conference and related medical solutions exhibition held annually in Chicago since 1915. This year, approximately 55,000 radiology specialists and industry professionals from 153 countries are expected to attend.

At this conference, Professor Choi Jin-wook of the Department of Radiology at Ajou University Hospital will present research results on the effectiveness of "Medical Insight+ Brain Hemorrhage." In the study, Professor Choi introduces the high completeness of "Medical Insight+ Brain Hemorrhage," which analyzes brain CT images within seconds and immediately identifies the location and abnormalities of hemorrhages with over 97% accuracy.

This software analyzes patient brain CT images and presents the possibility of brain hemorrhage disease as a numerical value from 0 to 100%, with abnormal areas highlighted by color or outlines. It also guides medical staff with a 7-level severity scale to support rapid image interpretation and response. Even small and subtle hemorrhages that are easy to miss are interpreted at the level of neurocranial imaging specialists, enabling medical staff to provide timely treatment during the golden hour.

SK C&C developed the deep learning algorithm using the "image segmentation" technique, part of the "Vision AI" technology applied in this software, with neurocranial imaging specialists from Seoul National University Hospital and Ajou University Medical Center participating in AI model data training and validation. Over 100,000 brain CT image data were utilized during the development process.

SK C&C expects to promote cooperation with hospitals and medical institutions worldwide through this conference. It also plans to proceed with the U.S. Food and Drug Administration (FDA) approval process next year.

This content was produced with the assistance of AI translation services.